Drugs / SCTC21C
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06252298 | Feb 2024 → Aug 2025 overdue | hematopoietic and lymphoid system neoplasm | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07538154 | Apr 2026 → Apr 2027 expected | systemic lupus erythematosus | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06774664 | Jan 2025 → Sep 2027 expected | IgA glomerulonephritis | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07388602 | Jan 2026 → Dec 2027 expected | amyloidosis | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07297329 | Dec 2025 → Dec 2027 expected | plasma cell myeloma | Sinocelltech Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCTC21C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06252298 ↗ |
| Route | Subcutaneous | “SCTC21C is injected to the participants subcutaneously” NCT06252298 ↗ |